Medi Aimer Pharmaceutical Private Limited
Founded in 2023 and headquartered in Uttar Pradesh, India.
2023 | Lucknow, Uttar Pradesh (India) | Active
Medi Aimer Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 1 Year 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.50 M
About Medi Aimer Pharmaceutical
Medi Aimer Pharmaceutical Private Limited (MAPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 May 2023 (One year and nine months 20 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Rahul Srivastava and Prabhat Ranjan serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U47721UP2023PTC181936
- Company No.
181936
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 May 2023
- Date of AGM
07 Nov 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Pharma
Who are the key members and board of directors at Medi Aimer Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Srivastava  | Director | 11-May-2023 | Current |
| Prabhat Ranjan | Director | 11-May-2023 | Current |
Financial Performance of Medi Aimer Pharmaceutical.
Enhance accessibility to Medi Aimer Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Medi Aimer Pharmaceutical?
Unlock access to Medi Aimer Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
Open Charges
₹0.50 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Nov 2024 | State Bank Of India | ₹0.50 M | Open |
How Many Employees Work at Medi Aimer Pharmaceutical?
Unlock and access historical data on people associated with Medi Aimer Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medi Aimer Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medi Aimer Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.